CA
NZ
UK
AU
IND
US
BrightSpring Health Services (NASDAQ:BTSG) traded at US$63.80 as of 8 October 2026, against an analyst consensus price target of US$71.53, an implied upside of approximately +12.1%.
● The round backs an early-stage life-sciences business.
● The deal covers DevOps and agentic-AI tooling.
● Oculis signed an asset purchase agreement for Privosegtor (ACT-01) and a preclinical candidate, ACT-02.
●Net Incomewas $15.7 million, against a $43.7 million loss a year earlier.
● Second-quarterRevenuewas $343,639, up from $56,325 in the first quarter.
● Cash, equivalents and marketable securities were $285.2 million.
● 2026 revenue guidance of $2.4 billion to $2.6 billion was reiterated.
● No confirmedEarningsrelease, contract win, guidance update, or analyst action was established to coincide with the move.
● NoEarningsreport, guidance change, product approval, financing, or management announcement has been verified to coincide with the session.
Please wait processing your request...